Malarial Vaccines Utilizing Antigen/Adjuvant Display on Viral-Like Particles
Small Business Information
Agave BioSystems, Inc.
P.O. Box 100, Ithaca, NY, -
AbstractRecent studies have suggested the potential of improved malarial vaccines by use of the viral-like particle (VLP)-linked immunogen approach. The VLP technology is being utilized for the development of vaccines for a variety of diseases. Agave BioSystems is creating a novel platform for development of malarial vaccines consisting of a VLP displayed malarial antigen/adjuvant based on the Norwalk virus (NV) capsid protein. The VLP will be engineered to express a candidate antigen in combination with a peptide adjuvant. These VLPs will be characterized, purified and delivered for testing of efficacy to stimulate cellular and humoral immune responses.In the Phase I, Agave BioSystems successfully demonstrated proof-of concept for this novel platform.
* information listed above is at the time of submission.